Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

September 9, 2019

PUBLICATION: Transl Oncol. 2019 Sep 9;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. AUTHORS: Slembrouck L., Darrigues L., Laurent C., Mittempergher L., Delahaye L.J., Vanden Bempt I., Vander Borght S., Vliegen L., Sintubin P., Raynal V., Bohec M., Reyes C., Rapinat A., Helsmoortel C., Jongen L., Hoste G., Neven P., Wildiers H., Smeets A., Nevelsteen I., Punie K., Van Nieuwenhuysen E., Han…

Read more

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

September 1, 2019

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue 5, Pages 808–823. AUTHORS: Lorenza Mittempergher, Leonie J.M.J. Delahaye, Anke T. Witteveen, Jacob B. Spangler, Fariet Hassenmahomed, Sammy Mee, Soufiane Mahmoudi, Jiang Chen, Simon Bao, Mireille H.J. Snel, Sandra Leidelmeijer, Naomi Besseling, Anne Bergstrom Lucas, Carlos Pabón-Peña, Sabine C. Linn, Christa Dreezen, Diederik Wehkamp, Bob Y. Chan,…

Read more

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline

August 1, 2019

PUBLICATION: Journal of Clinical Oncology 37, no. 22 (August 01, 2019) 1965-1977. DOI: 10.1200/JCO.19.00948. AUTHORS: N. Lynn Henry, MD, PhD; Mark R. Somerfield, PhD; Vandana G. Abramson, MD; Nofisat Ismaila, MD; Kimberly H. Allison, MD; Carey K. Anders, MD; Diana T. Chingos, MS, MFA; Andrea Eisen, MD; Bruno L. Ferrari, MD; Thomas H. Openshaw, MD; Patricia A.…

Read more

The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer

June 17, 2019

PUBLICATION: Ann Surg Oncol (2019) 26: 3495. https://doi.org/10.1245/s10434-019-07511-8. AUTHORS: J.E.C. van Steenhoven, A. Kuijer, K. Schreuder, S.G. Elias, P.J. van Diest, E. van der Wall, S. Siesling, T. van Dalen SUMMARY: A Netherlands Cancer Registry study correlated the increased use of MammaPrint led to decreased chemotherapy use, especially for LN+ and younger women. Read more: Steenhoven et al_2019_Annals…

Read more

ASCO June 5 2019: Race and response to neoadjuvant chemotherapy

June 5, 2019

AUTHORS: Raquel Nunes, Femke de Snoo, Lisette Stork-Sloots, Tina Treece, Christa Dreezen, William Audeh DESCRIPTION: Race and response to neoadjuvant chemotherapy according to MammaPrint risk African-American (AA) women with breast cancer have a less favorable prognosis, likely due to differences in tumor biology. The Neoadjuvant BReast Cancer Symphony Trial (NBRST, NCT01479101) was a prospective trial…

Read more

2019 ASCO FLEX Poster

June 4, 2019

AUTHORS: Gordan Srkalovic, Adam Brufsky, Jennifer Crozier, Mehran Habibi, Pat Whitworth, Charles Cox, Ian Grady, Nina D’Abreo, Sarah Untch, Erin Yoder, William Audeh, FLEX Investigators Group DESCRIPTION: Clinical Trial in Progress: The FLEX Big Data Platform Explores New Gene Expression Profiles and Investigator-Initiated Protocols in Early Stage Breast Cancer Genomic signatures are revolutionizing the definition,…

Read more

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

June 1, 2019

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: R. Wuerstlein, R. Kates, O. Gluz, E.M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland SUMMARY: MammaPrint and BluePrint test results strongly impacted physicians’ therapy…

Read more

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

April 18, 2019

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). AUTHORS: Floris H. Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N. M. Dinjens, Rene Bernards & Pat Whitworth ABSTRACT: Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that molecular subtyping using the 80-gene signature (80-GS) reclassified a…

Read more

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

March 27, 2019

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Science. AUTHORS: Kathleen A. Grant; Ettienne J. Myburgh; Elizabeth Murray; Fredrieka M. Pienaar; Martin Kidd; Colleen A. Wright; Maritha J. Kotze SUMMARY: Neither single-gene genomic mRNA nor IHC reporting of ER and PR status can replace the combined use of MammaPrint/BluePrint genomic molecular subtyping. -128 patients. Read more:…

Read more

2018 SABCS FLEX Trials in Progress Poster

December 5, 2018

AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Lomis, Pat Whitworth, Esther Rehmus, Gordon Srkalovic, Laura Lee, Peter Blumencranz, Paul Baron, Blanche Mavromatis, Sarah Untch, Lisa Blumencranz, Tina Treece, Erin Yoder, William Audeh. DESCRIPTION: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX) Genomic signatures are…

Read more